Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results